July 1977

Combined Calcitonin and Oral Phosphate Treatment for Hypercalcemia in Multiple Myeloma

Author Affiliations

From the Nephrology Section (Dr Broutbar), Veterans Administration Wadsworth Hospital Center, the Department of Nephrology (Dr Brautbar), University of California at Los Angeles, and Medical Department (Dr Luboshitzky), Rotchild Hospital, Haifa, Israel. Dr Luboshitzky is now with the Department of Endocrinology, Rambam Hospital, Haifa, Israel.

Arch Intern Med. 1977;137(7):914-916. doi:10.1001/archinte.1977.03630190068017

Hypercalcemia of multiple myeloma has been discussed widely in the medical literature. The role of calcitonin and phosphate in the treatment of hypercalcemia of multiple myeloma has not yet been studied to our knowledge, although experimental animal models have been pointing to the role of phosphate supplement to calcitonin treatment in multiple myeloma. A patient had multiple myeloma and hypercalcemia. The usual medical treatment for hypercalcemia failed; however, the treatment with combined orally administered phosphate and calcitonin was successful. The role of phosphate depletion in this setting is brought up as an important factor in the failure of calcitonin therapy.

(Arch Intern Med 137:914-916, 1977)